Vineet Agarwal
Net worth: - $ as of 2024-04-29
Profile
Vineet Agarwal is currently the Chief Financial Officer at Korro Bio, Inc. (United States) since 2021.
He is also the Treasurer, Chief Financial & Accounting Officer at Korro Bio, Inc. since 2023.
Previously, he worked as the Executive Director-Biotech Investment Banking at 09143628 Ltd.
from 2019 to 2021.
He also held the position of Executive Director at JPMorgan Chase & Co. from 2019 to 2021.
Mr. Agarwal holds an MBA from the Institute of Management Technology and an undergraduate degree from Shri Ram College of Commerce.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
-.--% | 2024-04-16 | 0 ( -.--% ) | - $ | 2024-04-29 |
Vineet Agarwal active positions
| Companies | Position | Start |
|---|---|---|
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 2021-04-30 |
Former positions of Vineet Agarwal
| Companies | Position | End |
|---|---|---|
| 09143628 Ltd. | Corporate Officer/Principal | 2021-04-30 |
| JPMORGAN CHASE & CO. | Director/Board Member | 2021-04-30 |
Training of Vineet Agarwal
| Institute of Management Technology | Masters Business Admin |
| Shri Ram College of Commerce | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| JPMORGAN CHASE & CO. | Finance |
| Private companies | 2 |
|---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
| 09143628 Ltd. | Finance |
- Stock Market
- Insiders
- Vineet Agarwal
